Clinical Trial Update: MK3207 for Treatment of Acute Migraines (3207-005) [Phase 2]

View source ↗

Summary

Merck's MK-3207 Phase 2 trial for acute treatment of migraines has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• MK-3207

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Migraine | Phase 2 | Status: COMPLETED | Results posted: 2010-11-22